NASDAQ · Drug Manufacturers - Specialty & Generic · USD
InMed Pharmaceuticals Inc. (INM) Stock Analysis
InMed Pharmaceuticals Inc. (INM) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
INM Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.32
- Previous Close
- $1.34
- Day's Range
- 1.32–1.39
- 52-Week Range
- 0.58–2.33
- Volume
- 26.41K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.93
Valuation
- Market Cap
- $7.47M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.84
Financials (FY)
- Revenue (FY)
- $4.94M+7.50%
- Net Income (FY)
- −$8.16M
- Shares Outstanding
- 5.49M
- 1-Year Return
- −37.04%
Dividend and dates
- Earnings Date
- November 5, 2026estimated
- Avg Volume
- 914.64K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, INM closed at $1.36, −37.04% over 1 year.
InMed Pharmaceuticals Inc. (INM) has a market capitalization of $7.47M.
In fiscal 2025, INM reported revenue of $4.94M.
INM Stock Return by Calendar Year
InMed Pharmaceuticals Inc. (INM) 10-year return: what $10,000 became
- 1 year
- $10,000 $6,296
- −37.04%
- 5 years
- $10,000 $14
- −99.86%
- 10 years
- $10,000 $6
- −99.94%
If you had invested $10,000 in InMed Pharmaceuticals Inc. (INM) 10 years ago, at the close on October 21, 2016, it would have been worth $6 at the close on October 21, 2026: −99.94% in total, −52.11% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +28.30% |
| 2025 | −77.64% |
| 2024 | −43.03% |
| 2023 | −79.41% |
| 2022 | −93.83% |
| 2021 | −60.18% |
| 2020 | −44.61% |
| 2019 | −29.41% |
| 2018 | −76.06% |
| 2017 | +526.47% |
| 2016 (partial year) | +157.58% |
As of October 21, 2026.
INM Revenue and Earnings by Fiscal Year
FY ends June| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $4.94M | −$8.16M | −165.1% |
| 2024 | $4.60M | −$7.68M | −166.9% |
| 2023 | $4.14M | −$7.95M | −192.2% |
| 2022 | $1.09M | −$18.60M | −1,707.3% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $4.94M | $1.71M | −$7.92M | −$8.16M | −165.1% |
| 2024 | $4.60M | $1.10M | −$8.13M | −$7.68M | −166.9% |
| 2023 | $4.14M | $1.40M | −$8.38M | −$7.95M | −192.2% |
| 2022 | $1.09M | $543.55K | −$13.79M | −$18.60M | −1,707.3% |
Annual figures as reported, in the company's reporting currency. As of June 30, 2025.
Recent News
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
YahooInMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - Specialty & Generic Stocks
Takeda Pharmaceutical Company Limited
$63.67B
TEVATeva Pharmaceutical Industries Limited
$47.37B
HLNHaleon plc
$44.06B
ZTSZoetis Inc.
$32.90B
UTHRUnited Therapeutics Corporation
$24.17B
VTRSViatris Inc.
$21.19B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B